{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:09Z","timestamp":1777934649884,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Irinotecan is chemotherapeutic agent often used in abdominal cancers such as colorectal and pancreatic cancers. While often associated with non-central nervous system (CNS) adverse effects, in rare cases it may present with paresthesias and dysarthrias. In one case, a patient received an irinotecan-containing regimen (fluorouracil, irinotecan, oxaliplatin) and experienced several neurotoxic effects, which was successfully managed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>A female patient with newly-diagnosed pancreatic cancer was started on fluorouracil, irinotecan, and oxaliplatin (modified FOLFIRINOX). She developed dysarthrias early on in the course. Causality assessment was conducted via the Naranjo criteria, yielding a score of 6, indicating a probable adverse reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>Initially managed with steroids and lorazepam, she was eventually given a prophylactic strategy of atropine 0.4\u2005mg and a longer infusion time of 3\u2005h instead of 90\u2005min with as needed lorazepam. This strategy alleviated the dysarthrias and the patient was able to complete 12 cycles of therapy, resulting in a partial response at the end of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Prolonging the infusion and giving prophylactic atropine may help to prevent these rare adverse effects of irinotecan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251324868","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:07:59Z","timestamp":1740712079000},"page":"1007-1010","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Irinotecan-induced dysarthria and management"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7050-3015","authenticated-orcid":false,"given":"Dennis","family":"Marjoncu","sequence":"first","affiliation":[{"name":"Methodist University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0314-066X","authenticated-orcid":false,"given":"Kerri","family":"Jones","sequence":"additional","affiliation":[{"name":"Methodist University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4869"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01364"},{"key":"e_1_3_3_5_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 3.2024."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-021-00526-7"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.45"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1231401"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-019-00106-z"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.30654\/MJGH.10001"},{"key":"e_1_3_3_11_2","volume-title":"Dysarthria","author":"American Speech-Language-Hearing Association (US)","year":"2020","unstructured":"American Speech-Language-Hearing Association (US). Dysarthria. Rockville, MD: ASHA, 2020."},{"key":"e_1_3_3_12_2","article-title":"Irinotecan-induced transient dysarthria in a patient with metastatic colorectal cancer: a case report","volume":"16","author":"Inting KAE","year":"2024","unstructured":"Inting KAE, Piano AN. Irinotecan-induced transient dysarthria in a patient with metastatic colorectal cancer: a case report. Cureus 2024; 16: e54416.","journal-title":"Cureus"},{"key":"e_1_3_3_13_2","volume-title":"Camptosar (irinotecan) [prescribing information]","year":"2023","unstructured":"Camptosar (irinotecan) [prescribing information]. New York, NY: Pharmacia & Upjohn Co, 2023."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000336156"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0644-7"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251324868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251324868","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251324868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:52Z","timestamp":1777689052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251324868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552251324868"],"URL":"https:\/\/doi.org\/10.1177\/10781552251324868","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}